Specialized Academic Departments and Institutes

ARQ National Psychotrauma Centre is a leading Dutch institute specializing in the treatment and research of complex psychotrauma and PTSD, with roots in addressing the psychological wounds of World War II since 1945 and now one of Europe's foremost psychotrauma centers. ARQ is one of nine European sites conducting MAPS-affiliated clinical trials of MDMA-assisted therapy for PTSD, and integrates medication-assisted approaches including MDMA and ketamine into its high-intensity trauma treatment programs in partnership with Leiden University Medical Center.

Academic Medical Center, commonly abbreviated AMC, is the Amsterdam academic hospital now operating as part of Amsterdam UMC. It combines tertiary care, medical education, and clinical research linked to the University of Amsterdam.

Amsterdam UMC (AMC-UvA) is one of the leading academic medical centers in the Netherlands, uniting the medical faculties of the University of Amsterdam and Vrije Universiteit Amsterdam with extensive clinical and translational research programs. The center has participated in psychedelic research including psilocybin microdosing studies, contributing to the Netherlands' growing academic investigation of psychedelic-assisted therapy.

Alef Trust is a UK-based transpersonal psychology educational institute founded by Emeritus Professor Brian Les Lancaster, offering an MSc in Consciousness, Spirituality & Transpersonal Psychology validated by Liverpool John Moores University and a professional certificate in Psychedelics, Altered States & Transpersonal Psychology taught by Dr. David Luke (Imperial College) and other leading researchers. The institute also offers collaborative PhDs and open learning courses integrating consciousness studies, parapsychology, and integrative healing traditions.

Attikon University General Hospital is one of Greece's largest university hospitals, affiliated with the National and Kapodistrian University of Athens Medical School and serving as a major center for specialist clinical care and research in the greater Athens region. The hospital has participated in clinical trials relevant to psychedelic medicine research, contributing to Greece's engagement with emerging psychiatric treatments including ketamine and esketamine for treatment-resistant depression.

The BC Centre on Substance Use (BCCSU) is an academic centre based in British Columbia that conducts research, develops clinical guidance and training, and supports evidence-based treatment and policy for substance use. It partners with health authorities, academic institutions, and community providers to improve care and reduce harms.

Beijing Chaoyang District Third Hospital is a Second Class B psychiatric specialist public hospital and the Chaoyang District Mental Health Center, providing mental health services to approximately 3.8 million district residents through seven inpatient wards and 35 departments. It has participated in multi-centre psychiatric clinical trials in China, including studies on cognitive-behavioural therapy for schizophrenia and depression outcomes research.

Beijing Daxing District Xinkang Hospital (北京市大兴区心康医院), also designated as the Daxing District Mental Health Institute, is a Class II Public Welfare psychiatric institution under Beijing's Daxing District Health Commission. Its Department of Psychiatry and Mental Health has contributed to Chinese psychiatric research, including studies on perinatal depression and other mental health outcomes.

Beijing Sanbo Brain Hospital (首都医科大学三博脑科医院) is a leading private specialised neurological hospital founded in 2004, affiliated with Capital Medical University as its Eleventh Clinical School, with 256 beds dedicated to neurosurgery, epilepsy, cerebrovascular disease, and functional neuroscience. Its anesthesiology department participates in multi-centre trials investigating ketamine and related anesthetic agents in neurosurgical settings.

UC Berkeley Center for the Science of Psychedelics (BCSP), founded in September 2020 by a multidisciplinary faculty group including neuroscientist Michael Silver and author Michael Pollan, conducting psilocybin research into cognition, perception, emotion, and their neural bases in the human brain. BCSP's four pillars of basic science, journalism, culture, and community have established it as a leading interdisciplinary hub for psychedelic research and public engagement, producing The Microdose newsletter and a global clinical trials map.

The James J. Peters VA Medical Center (Bronx VA) in New York is home to the Center for Psychedelic Psychotherapy and Trauma Research—a joint initiative with Mount Sinai's Icahn School of Medicine led by Dr. Rachel Yehuda—which pioneered the first FDA-approved randomized MDMA-assisted psychotherapy trial within the VA system and has conducted ketamine-based trials for chronic PTSD and suicidal ideation in veterans. The center is one of nine VA facilities participating in the expanded national VA psychedelic-assisted therapy research program.

Brooke Army Medical Center (BAMC) at Joint Base San Antonio is the US Army's flagship medical institution and the Department of Defense's only Level I Trauma Center, and has been a primary site in multi-center randomized controlled trials investigating ketamine for antidepressant-resistant PTSD in active duty military and veterans. BAMC researchers have also contributed to pilot studies on service members' perspectives on psychedelic-assisted therapies including MDMA and psilocybin for PTSD and traumatic brain injury.

Bruyère Health Research Institute is the academic research arm of Bruyère Health in Ottawa, Canada, fully affiliated with the University of Ottawa and specializing in palliative care, aging, and rehabilitation research—areas with growing overlap with psychedelic-assisted therapy applications. The institute contributed to a major Ontario population study examining schizophrenia risk following hallucinogen-related emergency department visits, generating safety evidence informing screening protocols for psychedelic clinical trials.

The California Institute of Integral Studies (CIIS) launched the world's first university-affiliated Psychedelic-Assisted Therapies and Research Certificate Program in 2015, establishing the gold standard for post-graduate psychedelic clinician training, with cohorts now also offered a B.S. in Psychedelic Studies and a KAP clinic. Based in San Francisco, CIIS is a non-profit graduate university pioneering integral approaches to consciousness, therapy, and psychedelic medicine.

The California Pacific Medical Center Research Institute (CPMCRI) is the academic research arm of California Pacific Medical Center in San Francisco, whose physician-scientists have contributed to the Bay Area’s psychedelic research ecosystem through advisory roles at the CIIS Center for Psychedelic Therapies and Research and collaborative ties to MAPS for evaluating MDMA-assisted therapy. CPMCRI conducts translational and clinical research across oncology, neurology, and psychiatry in partnership with UCSF and other Bay Area institutions.

The Center for Medicinal Cannabis Research (CMCR) is a California state-funded research program at UC San Diego that rigorously evaluates the medical efficacy and safety of cannabis and cannabinoids through placebo-controlled clinical trials, with regulatory expertise in Schedule I research that overlaps with psychedelic medicine. CMCR has been cited in psychedelic trial contexts for its methodological framework and experience navigating DEA/FDA processes for controlled-substance clinical research applicable to psilocybin and MDMA studies.

The Center for the Neuroscience of Psychedelics at MGH (Mass General Brigham) focuses on understanding how psychedelics impact brain structure and function to optimize treatments for mental illnesses. Led by Dr. Jerrold Rosenbaum, their initial research concentrates on psilocybin for treatment-resistant depression.

The Central Institute of Mental Health (ZI Mannheim) is a leading German psychiatric research institute affiliated with Heidelberg University, and under Prof. Dr. Gerhard Gründer is one of Europe’s foremost centers for psychedelic research—co-leading EPIsoDE, Germany’s first federal government-funded (BMBF, €2.2M) Phase II RCT of psilocybin for treatment-resistant depression, and receiving one of the first compassionate-use approvals for psilocybin in Germany and the EU, with results published in Lancet Psychiatry in 2025. The institute also conducts molecular neuroimaging research on MDMA and psilocybin mechanisms, and has reported successful ketamine treatment outcomes in treatment-resistant depression.

The Central Institute of Mental Health (Zentralinstitut für Seelische Gesundheit, ZI) is a psychiatric research and treatment center in Mannheim affiliated with the Medical Faculty Mannheim of Heidelberg University, providing research, teaching and clinical services in psychiatry, psychotherapy, child and adolescent psychiatry, psychosomatic medicine and addiction medicine.

GHU Paris Psychiatrie et Neurosciences (the current form of historic Hôpital Sainte-Anne) is France's leading university psychiatric hospital, pioneering psychedelic research under Jean Delay from the 1930s and now leading a 2024 ANR-funded psilocybin RCT aimed at dissociating therapeutic effects from acute psychedelic experience in treatment-resistant depression.

University hospital in Charleroi, Belgium affiliated with the Université Libre de Bruxelles. Participates in clinical trials for psychiatric and neurological conditions, including studies in the emerging area of esketamine and rapid-acting antidepressant therapies.

The Centre for Human Drug Research (CHDR) in Leiden, Netherlands is a world-class early-phase clinical research organization conducting approximately 60 trials per year, with a specialist psychiatry department that has become one of Europe’s leading sites for psychedelic compound research—including psilocybin, DMT, MDMA, and ketamine—using advanced tools such as the NeuroCart CNS battery and EEG to quantify pharmacodynamic endpoints. CHDR has conducted first-in-human studies with novel non-hallucinogenic neuroplastogens and intravenous DMT regimens, establishing it as a key early-phase partner for psychedelic drug development.

The Centre for Neurology Studies (CNS) is a private clinical research centre in Surrey, British Columbia, and one of Canada’s few dedicated neuroscience-focused clinical trial organizations, conducting Health Canada and FDA-approved studies in mental health, neurodegenerative disorders, and brain health. Operating within British Columbia’s growing clinical trials ecosystem, CNS has participated in research on novel psychiatric treatments relevant to the emerging psychedelic medicine field.

The Centre hospitalier de l’Université de Montréal (CHUM) is one of Canada’s leading academic health centres and home to psychiatrist Dr. Nicolas Garel, co-developer of the ‘Montreal Model’—a ketamine-assisted psychotherapy protocol for severe treatment-resistant depression that integrates psychedelic-inspired non-pharmacological adjuncts with structured psychiatric care. The MUSIK trial, conducted at CHUM and published in the British Journal of Psychiatry, demonstrated sustained 8-week depression relief and established that ketamine’s mystical experiences are central to its antidepressant mechanism.

The Center for Forensic Mental Health (CFMH) at Chiba University is a university research and education center focused on forensic psychiatry and social mental health. It provides training for medical and legal professionals and conducts research on diagnosis, treatment, and social systems concerning offenders with mental disorders and juvenile delinquency.

Children's National Research Institute is the research enterprise of Children's National Hospital in Washington, D.C., conducting translational and clinical research across pediatric disciplines. It is a site in the KESETT trial (Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial), investigating ketamine as an adjunctive therapy for refractory pediatric status epilepticus.

The Copenhagen Trial Unit (CTU), Centre for Clinical Intervention Research, is a non-specialty clinical research unit at Rigshospitalet (Copenhagen University Hospital), supporting rigorous randomised clinical trials and systematic reviews across all medical disciplines since 2000. Located at the same hospital campus as the Neurobiology Research Unit conducting active psilocybin neuroimaging studies, CTU provides the trial methodology, statistical expertise, and conduct infrastructure that enables clinical psychedelic research in Denmark.

Emotion Science (Emotion Science LLC, Denver) is an independent research and training entity associated with psychedelic and eating-disorder publications and clinician training led by Dr. Adele Lafrance.

The Brain Institute at the Federal University of Rio Grande do Norte is a Brazilian academic neuroscience center conducting translational research relevant to mental health and psychedelic science collaborations.

Miami public research university where Dr. Jerry B. Brown has taught interdisciplinary psychedelics courses since 1975, and Professor Joseph Lichter runs an Honors College Psychedelic Renaissance course covering therapeutic applications of psilocybin, MDMA, and ketamine. FIU also serves as one of 21 sites in a major national psychedelic clinical trial and hosts the Cannadelic conference — the first cannabis and psychedelics conference focused on next-generation research.

Vrije Universiteit Amsterdam (VU Amsterdam) is a major Dutch research university where neuroscientist Marco Aqil conducted the first psilocybin brain research in Amsterdam, demonstrating that psilocybin fundamentally alters visual processing by reducing cortical surround suppression. The university also hosts the Amsterdam Psychedelic Research Association (APRA) and offers an interdisciplinary honors course on the neuroscience, history, and therapeutic potential of psychedelics.

HaEmek Medical Center is a regional public hospital in Afula, northern Israel, affiliated with the Technion's Rappaport Faculty of Medicine and operated by Clalit Health Services, serving 700,000 citizens in the Jezreel Valley. The hospital is a designated site for MAPS Israel's multi-site MDMA-assisted group therapy trial for PTSD and moral injury in veterans, contributing to Israel's pioneering psychedelic-assisted therapy research infrastructure.

Harvard University hosts multiple psychedelic research initiatives including the Study of Psychedelics in Society and Culture (a $16M program), the MGH Center for the Neuroscience of Psychedelics, and the Harvard Law School POPLAR project addressing psychedelic policy reform. These programs span neuroscience, cultural studies, and legal advocacy to advance scientific and societal understanding of psychedelics.

The Vall d’Hebron Research Institute (VHIR) is the biomedical research arm of Hospital Universitari Vall d’Hebron in Barcelona, one of Spain’s largest tertiary academic medical centers. VHIR researchers are investigating ketamine-assisted psychotherapy for chronic pain comorbid with major depression, exploring both psychedelic-dose intramuscular and psycholytic-dose sublingual approaches.

ICEERS is a nonprofit research and policy organization focused on evidence generation, education, and legal-health support related to psychedelic and plant medicine use.

IESE Business School is a global graduate business school at the University of Navarra, based in Barcelona, that contributes to psychedelic research through the PsyPal consortium. As part of the first EU-funded psychedelic clinical study (€6.5M, 19 partners), IESE hosts design thinking workshops and brings expertise in health economics, organizational implementation, and stakeholder strategy to support the psilocybin palliative care trial.

French National Institute of Health and Medical Research (INSERM), a national public biomedical research organization with active discourse and research engagement on psychedelic medicine.

The Inner Mongolia Autonomous Region Mental Health Center is a government-affiliated regional psychiatric institution in Hohhot, China, affiliated with the School of Mental Health at Inner Mongolia Medical University. The center has participated in clinical research on esketamine for treating depressive episodes with suicidal ideation in patients with mood disorders.

The Institute for Integration of Medicine & Science (IIMS) at UT Health San Antonio is the institution's NIH-funded Clinical and Translational Science Award hub, supporting multi-disciplinary translational research across South Texas. The institute has been involved in a clinical trial combining esketamine with prolonged exposure therapy for post-traumatic stress disorder.

The Institute of Psychology of the Polish Academy of Sciences is a Warsaw-based research institute that conducts basic and applied research across psychological sciences (cognitive, developmental, clinical, social and related fields).

A Brazilian non-profit research institute (founded 2011) based in São Paulo that conducts research and education on psychedelic-assisted psychotherapy and trains health professionals for related clinical research.

The Integrative Psychiatry Institute (IPI), co-founded by Will Van Derveer MD and Keith Kurlander, is a leading US psychedelic-assisted therapy training organization that has trained over 2,200 healthcare providers in 300-hour programs covering ketamine, MDMA, and psilocybin. IPI's psilocybin track was among the first approved by the Oregon Health Authority, and the institute collaborates with the Usona Institute and ASKP³ to develop evidence-based curricula.

ICEERS (International Center for Ethnobotanical Education, Research and Service) is a nonprofit supporting ethnobotanical research, policy engagement, and community-informed programming around ayahuasca, iboga, and related plant medicines.

A research center within Johns Hopkins University (School of Medicine) that conducts scientific studies on psychedelic compounds, their effects on brain function and consciousness, and their therapeutic potential for mental health conditions.

Karolinska Institutet is Sweden's largest medical university and a leading European hub for psychedelic research, with the Centre for Psychiatry Research led by Prof. Johan Lundberg conducting PSIPET — Sweden's first RCT of psilocybin for major depressive disorder. The institute participates in the Nordic Network for Psychedelic Science and launched a doctoral course in psychedelic science in 2025.

Louisiana State University Health Sciences Center in New Orleans (LSU Health New Orleans) is an academic health sciences center in New Orleans, Louisiana, offering medical, dental, nursing, public health, allied health, and graduate education alongside clinical services and biomedical research.

The non-profit research arm of Harbor-UCLA Medical Center in Torrance, California, the Lundquist Institute hosted Dr. Charles Grob's landmark 2004–2008 pilot study—one of the first modern psilocybin trials for anxiety in advanced-stage cancer patients, published in Archives of General Psychiatry (2011). The Institute subsequently received $1.75M from the Steven & Alexandra Cohen Foundation and a Samberg Foundation gift to co-lead a new multi-site psilocybin palliative care trial alongside NYU's Dr. Anthony Bossis.

One of the world’s leading comprehensive cancer centers, affiliated with UT Health Houston, MD Anderson Cancer Center has emerged as a site for landmark psychedelic research; the institution is conducting psilocybin-assisted psychotherapy trials in patients with advanced cancer and co-investigates NeuroGuard—a novel trial exploring psilocybin to prevent chemotherapy-induced peripheral neuropathy.

The METIV Israel Psychotrauma Center is a leading authority in trauma treatment and research. The center is involved in exploring MDMA-assisted therapy for PTSD, aligning with a broader mission to develop advanced treatment methods for trauma-related conditions exacerbated by conflict.

MercyOne Des Moines Medical Center is a 622-bed hospital in Des Moines, Iowa, certified as a Level II Area Trauma Care Facility and part of the Trinity Health system. The center served as the primary site for a clinical study of antidepressant ketamine administered in the emergency department for patients presenting with severe depression or suicidal ideation (NCT04266288), and subsequently integrated Spravato (esketamine) nasal spray into its behavioral health services.

Public university in St. Joseph, Missouri, home to Dr. Christine Ziemer's pioneering undergraduate courses in psychedelic-assisted psychotherapy and transpersonal psychology covering psilocybin, LSD, MDMA, ketamine, and ayahuasca research and therapeutic applications. Dr. Ziemer founded the Psychedelic Educators Network, serves as executive director of the Psychedelic Society of Kansas City, and supports harm reduction through the Fireside Project and Zendo Project, making Missouri Western a notable hub for Midwestern psychedelic education.

NYU Langone Health’s Center for Psychedelic Medicine (NYU CPM) conducts health-focused translational research, education, and training on the therapeutic use of psychedelic drugs across psychiatry, medicine, and preclinical science. It supports clinical trials and a research training program to develop investigators and clinicians in the field.

Naropa University is a Boulder, Colorado Buddhist-inspired private university founded in 1974 that emerged as a national leader in psychedelic education through its Naropa Center for Psychedelic Studies (NCPS) and undergraduate Psychedelic Studies Minor. The NCPS separated in late 2024 to become the independent Memoru Center for Visionary Healing Arts, while Naropa continues to offer its contemplative-approach psychedelic studies minor and transpersonal psychology graduate programs.

The Nathan S. Kline Institute for Psychiatric Research (NKI) is a research institute operated by the New York State Office of Mental Health in Rockland County, New York. It conducts biological, clinical, and computational research on psychiatric disorders and collaborates with academic partners such as New York University.

The National Center for PTSD (NC-PTSD) is a US Department of Veterans Affairs centre of excellence for research, education, and training on post-traumatic stress disorder, operating across seven VA medical centre sites with a focus on evidence-based assessment and treatment. The Centre has supported mechanistic ketamine research in military and veteran populations, including an investigation of AMPA receptor blockade on ketamine’s anti-suicidal effects relevant to veteran mental health crises.

U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.

The National Institute of Neurology and Neurosurgery (INNN; Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez) is a Mexican federal specialist hospital and research institute in Mexico City dedicated to the diagnosis, treatment, and study of neurological and neurosurgical conditions. The INNN has been a centre for ketamine research in treatment-resistant depression, conducting trials evaluating intravenous ketamine dosing regimens for patients unresponsive to standard antidepressant therapy.

U.S. federal institute setting addiction-research priorities and portfolios, including psychedelic-related investigations.

Naval Medical Center Camp Lejeune is the primary U.S. military hospital serving Marine Corps Base Camp Lejeune in Jacksonville, North Carolina, operating ACGME-accredited residency programs in family medicine and psychiatry. The center sponsored NCT04260607, a randomized controlled trial of IV ketamine versus placebo for rapid stabilization of acutely suicidal patients presenting to the emergency department.

State-funded psychiatric research institute affiliated with Columbia University, located in New York City. A key site for psilocybin clinical trials including the landmark COMP360 study for treatment-resistant depression, and conducts broader research on LSD, DMT, ayahuasca, and ketamine through Columbia's Depression Evaluation Service.

Ontario Shores Centre for Mental Health Sciences is a specialized mental health facility in Whitby, Ontario affiliated with the University of Toronto Department of Psychiatry, offering investigational ketamine infusion therapy for treatment-resistant depression. The centre has conducted trials comparing ketamine to ECT and combining IV ketamine with internet-based CBT (Ket-CBT) for suicidality in TRD, and holds the world's first Level 7 EMR maturity validation for a mental health facility.

Oregon Research Institute's Center for Evaluation Services (ORI CES) is a 501(c)(3) non-profit research unit based in Eugene, Oregon that provided methodological and evaluation support to the SAMATI (Social Anxiety MDMA-Assisted Therapy Investigation) trial — an investigator-initiated study by Portland Psychotherapy exploring MDMA-assisted therapy for generalized social anxiety disorder, with study drug supplied by MAPS PBC.

Orygen is an Australian youth mental health organisation and research centre focused on prevention, early intervention, clinical care, and translational research for young people with mental ill-health.

The Ottawa Hospital Research Institute (OHRI) is the research arm of The Ottawa Hospital and affiliated with the University of Ottawa, conducting clinical and translational research spanning 16 departments and over 1,700 scientists and trainees. OHRI has contributed to psilocybin research for psychological and existential distress in palliative care, part of Canada's expanding academic psychedelic medicine research.

The Peter Boris Centre for Addictions Research (PBCAR) is a joint addiction research centre of McMaster University and St. Joseph's Healthcare Hamilton in Canada, directed by Dr. James MacKillop. PBCAR is conducting a Phase 2 clinical trial of psilocybin-assisted psychotherapy — two 25 mg psilocybin sessions combined with an 8-week Motivational Enhancement Therapy program — for cannabis use disorder.

The Pharmaceutical Research Unit (PRU) is the first contract research organization established in Jordan (1993), headquartered in Amman and accredited by the US FDA, EU authorities, and multiple MENA health agencies. PRU served as the clinical site and collaborating organization for Lobe Sciences' Phase 1 first-in-man pharmacokinetic study of psilocin mucate (L-130), a stabilized psilocin salt with near-100% bioavailability investigated as a low-dose at-home therapeutic.

HaEmek Medical Center's Psychedelic Research and Treatment Center is a pioneer in MDMA-assisted therapy (MDMA-AT) for combat-related PTSD. It is notable for offering group therapy models and utilizes advanced neuroimaging tools (EEG/fMRI) to monitor clinical outcomes and brain mechanisms.

Roswell Park Comprehensive Cancer Center in Buffalo, NY operates a Psychedelic Science Initiative (PSI) conducting research on psilocybin and ketamine for cancer patients; active trials include an open-label psilocybin microdosing study for chronic cancer pain and opioid reduction, a Phase 2 trial of the novel psychedelic RE104 for adjustment disorder in cancer patients, and a palliative esketamine clinic for co-morbid treatment-resistant depression.

The San Francisco Department of Public Health is the public health agency of the City and County of San Francisco, operating clinics, HIV/AIDS programs, and behavioral health services for over 125,000 patients annually; through its Behavioral Health Services division, it is conducting the KARE (Ketamine-Assisted Recovery) trial investigating ketamine-assisted psychotherapy for methamphetamine use disorder in publicly-insured adults with or at risk for HIV, integrating harm reduction principles with neuroplasticity-based addiction treatment.

Shalvata Mental Health Center is a 114-bed comprehensive psychiatric hospital founded in 1956 in Hod HaSharon, Israel, affiliated with Clalit Health Services and the Sackler Faculty of Medicine at Tel Aviv University; it is one of Israel's most active psychedelic research sites, having conducted trials comparing intranasal versus intravenous ketamine administration, MDMA-assisted psychotherapy for borderline personality disorder, and ketamine combined with cognitive behavioral analysis system of psychotherapy (CBASP) for chronic treatment-resistant depression.

Israel's largest hospital and a major academic medical center affiliated with Tel Aviv University. A key site for MDMA-assisted psychotherapy trials through MAPS Israel and other research programs, as well as ketamine studies for treatment-resistant depression.

Southern Methodist University (SMU) is a private research university in Dallas, Texas, offering the course "Plants of the Gods: Religion and Psychedelics" through its Religious Studies department, taught by University Distinguished Teaching Professor Dr. G. William Barnard. The course examines the historical and cultural significance of entheogenic plants — including peyote, ayahuasca, and psilocybin mushrooms — across diverse religious traditions.

Stella (originally Stella Center, now Stella Mental Health) is a US-based psychiatric practice specializing in interventional psychiatry for PTSD, depression, and anxiety, with a particular focus on military veterans and Special Operations Forces personnel. The organization pioneered the Dual Sympathetic Reset (DSR) — an advanced stellate ganglion block (SGB) protocol — alongside ketamine therapy and Spravato, and is involved in the Reversal of Battle-Related Aging (ROBRA) study investigating interventional approaches to combat-related neurological decline in Special Operations Forces cohorts.

Major academic hospital in Toronto affiliated with the University of Toronto. Contributes to Canadian psychedelic research through its Odette Cancer Centre's involvement in psilocybin trials for cancer-related distress, and its Department of Psychiatry's participation in CANMAT task forces on psychedelic treatments for depression.

A world-class scientific institution based in Lisbon, Portugal, operating under the Champalimaud Foundation. The Centre conducts cutting-edge research in neuroscience, cancer biology, and systems biology, while also providing clinical oncology services. Its Neuroscience Programme investigates the neural mechanisms of perception, cognition, and behavior.

An independent international research institute focused on preventing and treating the world's leading causes of death and disability. With centers in Australia, China, India, and the UK, the George Institute for Global Health conducts large-scale clinical trials and population health studies addressing cardiovascular disease, stroke, kidney disease, and mental health.

The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center is an independent, nonprofit biomedical research institute located on the Harbor‑UCLA campus in Torrance, California. It conducts translational and clinical research across areas such as cancer, infectious disease, and genomics and is affiliated with UCLA’s David Geffen School of Medicine.

The Neurobiology Research Unit (NRU) at Copenhagen University Hospital – Rigshospitalet is a leading neuroimaging center led by Prof. Gitte Knudsen. Specializing in PET and MRI studies of the serotonin system, NRU has conducted landmark research on how psilocybin and other psychedelics modulate brain function and serotonin receptor binding, establishing some of the field’s key mechanistic insights.

Academic medical center in Northeast Texas and part of The University of Texas System. Conducts clinical research across pulmonary medicine, trauma, cardiology, and neurology, and has participated in trials exploring psychedelic and ketamine-assisted therapies.

The Thompson Institute is a mental health and neuroscience research, education and clinical hub at the University of the Sunshine Coast that translates research into clinical programs and community training.

The University of Groningen's medical center (UMCG) is a leading European hub for psychedelic research, coordinating the EU-funded €6.5M PsyPal clinical trial studying psilocybin for psychological distress in palliative care patients. UMCG also hosts an annual interdisciplinary summer school in psychedelic research in collaboration with the OPEN Foundation and partner universities.

The University Medical Center Groningen (UMCG) is the academic hospital affiliated with the University of Groningen, providing tertiary and specialized patient care while conducting medical research and education. It is one of the largest university hospitals in the Netherlands and serves as the main academic medical center for the northern Netherlands.

The PsyPal project coordinators at UMCG are leading a major EU-funded multi-site clinical study investigating psilocybin therapy for psychological and existential distress in patients with progressive incurable illnesses, including ALS.

Major research university and academic medical center in Birmingham, Alabama. A key site in the first federally funded psilocybin trial in 50 years — a NIH/NIDA-funded multisite study on psilocybin for smoking cessation led by Dr. Peter Hendricks, alongside Johns Hopkins and NYU.

The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.

The Department (Clinic) of Psychiatry and Psychotherapy at the University of Debrecen Clinical Centre provides inpatient and outpatient psychiatric care and functions as a center for education and research in psychiatry and psychotherapy.

The University of Mississippi Medical Center (UMMC) is the health sciences campus of the University of Mississippi, located in Jackson, Mississippi. It is the state’s only academic medical center, providing medical education, research, and advanced clinical care.

UNSW and the Black Dog Institute are Australian academic and clinical research partners with programs in mental health and emerging psychedelic therapeutics research.

The University of Ottawa launched a groundbreaking one-year MA in Psychedelics and Consciousness Studies in 2024, jointly offered by the Faculty of Social Sciences and Faculty of Arts under co-directors Dr. Monnica Williams and Dr. Anne Vallely. The program builds on earlier microprograms in Psychedelic Science and Psychedelics & Spirituality Studies established since 2020, training licensed professionals, clergy, and researchers in therapeutic, spiritual, and academic dimensions of psychedelics.

The Department of Psychiatry at the University of Oxford is a clinical department within the Medical Sciences Division that conducts research, teaching, and clinical trials across psychiatry, neuroscience, and mental health. It is based at the Warneford Hospital site in Oxford, England.

The Penn Psychedelics Collaborative at the University of Pennsylvania is a multi-school consortium of researchers, clinicians, and faculty advancing transdisciplinary psychedelic science across Penn Medicine and Penn Nursing, including clinical trials of MDMA-assisted therapy and psilocybin research. Penn researchers are also leading the development of bioethical guidelines for psychedelic-assisted therapy and community implementation frameworks.

UT Southwestern Medical Center is a leading academic medical center in Dallas, Texas, combining research, education, and patient care. It houses the Peter O'Donnell Jr. Brain Institute and participates in clinical trials investigating ketamine and psychedelic-adjacent compounds for treatment-resistant depression and other neuropsychiatric conditions.

University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.

The University of Wisconsin Department of Family Medicine and Community Health is an academic clinical department supporting research and translational work in mental health, primary care, and related psychedelic medicine studies.

A research institute within Utrecht University's Faculty of Science in the Netherlands, conducting research on drug discovery, pharmacology, and pharmaceutical sciences. UIPS studies include the pharmacokinetics, toxicology, and neurobiological effects of psychoactive compounds, and contributes to translational research bridging laboratory pharmacology and clinical application.

Vanderbilt University Medical Center (VUMC) is a leading academic medical center in Nashville, Tennessee, known for its research strengths in neuroscience and psychiatry. It participates in clinical research on psychedelic-assisted therapies including psilocybin and MDMA for treatment-resistant depression, PTSD, and other psychiatric conditions.

NICM Health Research Institute is a research institute of Western Sydney University focused on integrative and complementary medicine, conducting preclinical, clinical and translational research to evaluate the quality, safety, and effectiveness of traditional and complementary therapies.

A research center within Yale School of Medicine focused on understanding the neuroscience of consciousness, mental health disorders, and the mechanisms of psychoactive substances. The Center for Brain and Mind Health bridges psychiatry and neuroscience to advance knowledge of brain-mind relationships and explore novel therapeutic approaches including psychedelic-assisted treatment at Yale.